leadf
logo-loader
viewOrthocell Ltd

Orthocell awarded US trademark for Ortho-ATI® cell therapy for treatment of chronic tendon injuries

The trademark will remain in force for an initial period of 10 years and may be renewed for successive periods of 10 years thereafter.

Orthocell Ltd - Orthocell awarded US trade mark for its Ortho-ATI® cell therapy for the treatment of chronic tendon injuries
The trademark application was accepted and registered in June 2020 under number 6,082,605

Orthocell Ltd (ASX:OCC) has been awarded the United States Divisional Trade Mark Registration for its Ortho-ATI® cell therapy for the treatment of chronic tendon injuries.

The trademark application, which was accepted and registered in June 2020, will remain in force for an initial period of 10 years and may be renewed for successive periods of 10 years thereafter.

Managing director Paul Anderson said: “We are delighted to receive this important trademark within the United States, which complements our strong intellectual property portfolio and our ongoing efforts to bring this exciting technology into the US market.

2019 Annual Quality Study

Early this month, the company released its 2019 Annual Quality Study, which indicated an 87.5% patient satisfaction rating using Ortho-ATI® cell therapy for the treatment of chronic tendon injuries of the shoulder and a 74.3% patient satisfaction rating in all patient groups including, elbow, hip, knee and ankle.

It indicated that 87.5% of shoulder patients were satisfied with how Ortho-ATI® relieved symptoms (ie chronic pain) and improved ability to perform everyday activities at home and at work.

Patient case studies

One of the patient case studies involved well-known AFL star, Daniel Kerr, who played 220 games for the West Coast Eagles between 2001 and 2013.

At the age of 28, he suffered a complete hamstring rupture, which doctor’s described as a “career-ending injury” but after exhausting traditional surgical and non-surgical treatments, he finally found Ortho-ATI®.

His story is detailed in the following video:

Quick facts: Orthocell Ltd

Price: 0.425 AUD

ASX:OCC
Market: ASX
Market Cap: $78.53 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Orthocell Ltd named herein, including the promotion by the Company of Orthocell Ltd in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Orthocell's Paul Anderson hails 'fantastic outcome' in CelGro nerve repair study

Orthocell Ltd's (ASX:OCC) Paul Anderson speaks to Proactive's Andrew Scott soon after announcing positive long-term clinical data for its CelGro® nerve repair study. The regenerative medicine company has decided that the clinical results have met the study objectives and has now closed...

4 days, 4 hours ago

2 min read